Implantable Biomaterials Market Report 2025

This Implantable Biomaterials market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The implantable biomaterials market size has grown rapidly in recent years. It will grow from $144.1 billion in 2024 to $165.43 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to clinical success and patient outcomes, tissue engineering progress, surface modification techniques, regulatory milestones, biodegradable materials introduction.

The implantable biomaterials market size is expected to see strong growth in the next few years. It will grow to $239.92 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to bioactive and bioresorbable materials, smart and responsive biomaterials, regulatory and safety standards, hybrid composite materials, tissue engineering advancements. Major trends in the forecast period include drug-eluting implants, biocompatibility advancements, 3d printing and customization, regenerative medicine focus, nanotechnology integration.

Government organizations' investment in the advancement of new biomaterials, as evidenced by allocations to projects such as Drexel University's USD 200,000 grant to the National Science Foundation, is a significant driver of growth in the implantable biomaterials market. This financial support fosters research on biomaterial-mediated control over macrophage behavior, influencing biomaterial vascularization. The backing from government entities is poised to fuel further advancements in implantable biomaterials.

The increase in cardiovascular disease cases is projected to drive the growth of the implantable biomaterial market. Cardiovascular disease encompasses a range of conditions that impact the heart and blood vessels. As the incidence of cardiovascular diseases rises, so does the demand for implantable biomaterials, which are essential for the treatment and management of these conditions. These materials are utilized in various medical devices and procedures to repair or replace damaged cardiovascular tissues. With more individuals facing cardiovascular issues, the need for effective and innovative biomaterials intensifies, leading to the development of better and more efficient implants that ultimately enhance patient outcomes and quality of life. For example, a report published in October 2022 by the World Heart Federation, a Switzerland-based non-governmental organization, projects that deaths from cardiovascular diseases could increase from 22.2 million to 32.3 million by 2050. Thus, the rise in cardiovascular disease cases is expected to propel the implantable biomaterial market forward.

Major players in the implantable biomaterial market are concentrating on developing innovative products, such as the Citregen biomaterial, to improve tissue repair and regeneration outcomes. Citregen biomaterial is a biodegradable and bioresorbable synthetic material utilized in implantable devices for tissue regeneration. For example, in December 2022, Stryker Corporation, a US-based pharmaceutical company, introduced the Citrefi Suture Anchor System. This innovative Citregen biomaterial is designed to enhance bone regeneration and support the natural healing process. The sterile-packed set of the Citrefi Suture Anchor System includes a cartridge with a preloaded implant and eyelet, a drill bit, a drill guide, and a pre-assembled inserter, which streamlines the surgical process. It features a disposable suture anchor with a resorbable biomimetic anchor body, engineered to improve pull-out strength compared to traditional suture anchors while minimizing chronic inflammation during recovery. This new system is specifically designed for foot and ankle surgical procedures.

In April 2022, Integer Holdings Corporation, a U.S.-based medical device company, successfully acquired Connemara Biomedical Holdings Teoranta for an undisclosed sum. This strategic acquisition positions Integer to control implantable biomaterial technology, fostering its growth in the medical device industry. Connemara Biomedical Holdings Teoranta, based in Ireland, specializes in the manufacturing of biomaterials for cardiovascular implants.

Major companies operating in the implantable biomaterials market include BASF SE, 3M Company, Medtronic plc, Evonik Industries AG, Stryker Corporation, DuPont de Nemours Inc., Celanese Corporation, Zimmer Biomet Holdings Inc., Koninklijke DSM NV, Arthrex Inc., DePuy Synthes Companies, Carpenter Technology Corporation, Corbion NV, GELITA AG, CoorsTek Inc., CeramTec GmbH, Orthofix Holdings Inc., Invibio Biomaterial Solutions plc, Keystone Dental Inc., KLS Martin SE & Co., Collagen Matrix Inc., Cam Bioceramics BV, Aap Implantate AG, Berkeley Advanced Biomaterials Inc., AdvanSource Biomaterials Corporation, Collagen Solutions plc, Surgival SL, SBM France SAS.

Implantable biomaterials are natural or synthetic materials utilized in medical applications to support, enhance, or replace damaged tissues or biological structures.

These materials encompass metallic, ceramic, polymers, and natural substances. Metallic implants, often preferred in orthopedic prosthesis, enhance biological activities and are favored over polymeric and traditional ceramic biomaterials. They find applications in dental, cardiovascular, ophthalmology, orthopedic, and other medical fields, used across hospitals, ambulatory surgical centers, and specialty clinics.

The implantable biomaterials market research report is one of a series of new reports that provides implantable biomaterials market statistics, including implantable biomaterials industry global market size, regional shares, competitors with an implantable biomaterials market share, detailed implantable biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the implantable biomaterials industry. This implantable biomaterials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the implantable biomaterials market in 2024. Western Europe was the second largest region in the global implantable biomaterials market report. The regions covered in the implantable biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The implantable biomaterial market consists of sales of glass-ceramic and bioactive glasses and calcium phosphate cements. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.